CCXI stock forecast
Our latest prediction for ChemoCentryx Inc's stock price was made on the Aug. 19, 2022 when the stock price was at 51.00$.
In the short term (2weeks), CCXI's stock price should underperform the market by -0.53%. During that period the price should oscillate between -8.62% and +8.98%.
In the medium term (3months), CCXI's stock price should underperform the market by -3.97%. During that period the price should oscillate between -19.67% and +17.45%.
Get email alertsCreate a solid portfolio with CCXI
About ChemoCentryx Inc
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
At the moment the company generates 9M USD in revenues.
On its last earning announcement, the company reported a loss of -1.00$ per share.
The book value per share is 0.56$
Three months stock forecastAug. 19, 2022
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9M | - | -131M | -1379.22% | -109M | -1.00 | - | - | 71M | 0.56 | - | - | - |